Prof. Dr. Beat Thürlimann
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
Dabakuyo-Yonli T, Russell N, Roché H, Pruneri G, Penault Llorca F, Offersen B, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J, Untch M, Thürlimann B, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.
Feb 27, 2015Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
Feb 27, 2015Ann Oncol 2015; 26:873-9
Dabakuyo-Yonli T S, Russell N S, Roché H, Pruneri G, Penault Llorca F, Offersen B V, Negreiros I, Michiels S, Macgrogan G, Kirkove C, Schmitt F, Servent V, Bellera C, Mathoulin-Pélissier S, Bonnetain F, Yarnold J, Wildiers H, van Tienhoven G, van der Hage J A, Untch M, Thürlimann Beat, Jacot W, Gutowski M, Gligorov J, Bonnefoi H, Bogaerts J, Bliss J, A'Hern R, Cardoso F, Azria D, Asselain B, Poortmans P, Cameron D, Brain E, Cardoso M J, Filleron T, Delaloge S, Debled M, De Azambuja E, Dalenc F, Dal Lago L, Cufer T, Coleman R, Chibaudel B, Gourgou-Bourgade S
Adjuvant bisphosphonates in breast cancer treatment
Knauer M, Thürlimann B. Adjuvant bisphosphonates in breast cancer treatment. Breast Care (Basel) 2014; 9:319-22.
Oct 1, 2014Adjuvant bisphosphonates in breast cancer treatment
Oct 1, 2014Breast Care (Basel) 2014; 9:319-22
Knauer Michael, Thürlimann Beat
Bone targeted therapy in breast cancer - an old concept but still much to do
Huober J, Thürlimann B. Bone targeted therapy in breast cancer - an old concept but still much to do. Breast Care (Basel) 2014; 9:310.
Oct 1, 2014Bone targeted therapy in breast cancer - an old concept but still much to do
Oct 1, 2014Breast Care (Basel) 2014; 9:310
Huober Jens, Thürlimann Beat
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Templeton A, Ruhstaller T, Thürlimann B, Zaman K, von Moos R, Rochlitz C, Winterhalder R, von Rohr L, Müller A, Winkler A, Borner M, Dietrich D, Beyeler M, Hsu Schmitz S, Sun H, Surber C, Ribi K, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 2014; 23:244-9.
Mar 20, 2014Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Mar 20, 2014Breast 2014; 23:244-9
Templeton Arnoud, Ruhstaller Thomas, Thürlimann Beat, Zaman Khalil, von Moos Roger, Rochlitz Christoph, Winterhalder Ralph C, von Rohr Lukas, Müller Andreas, Winkler Annette, Borner Markus, Dietrich Daniel, Beyeler Michael, Hsu Schmitz Shu-Fang, Sun Hong, Surber Christian, Ribi Karin, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Jörger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, Cerny T. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. Eur J Clin Pharmacol 2014; 70:719-25.
Mar 11, 2014Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
Mar 11, 2014Eur J Clin Pharmacol 2014; 70:719-25
Jörger Markus, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem Stefan, Thürlimann Beat, Cerny Thomas
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 2014; 144:321-9.
Feb 1, 2014Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Feb 1, 2014Breast Cancer Res Treat 2014; 144:321-9
Decensi Andrea, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Price Karen N, Johansson Harriet, Zaman Khalil, Schönenberger Astrid, Debled Marc, Campone Mario, Monnier Alain, Tondini Carlo, McIntosh Christina, Thürlimann Beat, Guerrieri-Gonzaga Aliana, Sun Zhuoxin, Aebi Stefan
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Aebi S, Mamounas E, Geyer C, Price K, Coates A, Gelber R, Rastogi P, Wolmark N, Wapnir I, Murray E, Thürlimann B, Cañada J, Gelber S, Anderson S, Láng I, Robidoux A, Martín M, Nortier J, Paterson A, Rimawi M, CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 2014; 15:156-63.
Jan 16, 2014Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Jan 16, 2014Lancet Oncol 2014; 15:156-63
Aebi Stefan, Mamounas Eleftherios P, Geyer Charles E, Price Karen N, Coates Alan S, Gelber Richard D, Rastogi Priya, Wolmark Norman, Wapnir Irene L, Murray Elizabeth, Thürlimann Beat, Cañada José Manuel Baena, Gelber Shari, Anderson Stewart J, Láng István, Robidoux Andre, Martín Miguel, Nortier Johan W R, Paterson Alexander H G, Rimawi Mothaffar F, CALOR investigators
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Huober J, Thürlimann B, Gelber R, Colleoni M, Coates A, Goldhirsch A, Price K, Wardley A, Smith I, Láng I, Neven P, Forbes J, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 2013; 143:159-69.
Dec 5, 2013Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Dec 5, 2013Breast Cancer Res Treat 2013; 143:159-69
Huober J, Thürlimann Beat, Gelber R D, Colleoni M, Coates A S, Goldhirsch A, Price K N, Wardley A, Smith I, Láng I, Neven P, Forbes J F, Bonnefoi H, Ejlertsen B, Wu J, Giobbie-Hurder A, Rabaglio M, Cole B F, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss
Zaman K, Thürlimann B, Aebi S. Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss. J Clin Oncol 2013; 31:3440-1.
Aug 5, 2013Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss
Aug 5, 2013J Clin Oncol 2013; 31:3440-1
Zaman Khalil, Thürlimann Beat, Aebi Stefan
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, Senn H, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23.
Aug 4, 2013Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Aug 4, 2013Ann Oncol 2013; 24:2206-23
Goldhirsch A, Winer E P, Coates A S, Gelber R D, Piccart-Gebhart M, Thürlimann Beat, Senn H-J, Panel members
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
Templeton A, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC cancer 2013; 13:153.
Mar 25, 2013Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
Mar 25, 2013BMC cancer 2013; 13:153
Templeton Arnoud J, Thürlimann Beat, Baumann Michael, Mark Michael, Stoll Sarah, Schwizer Madeleine, Dietrich Daniel, Ruhstaller Thomas
Chemotherapy regimens in early breast cancer: major controversies and future outlook
Jörger M, Thürlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013; 13:165-78.
Feb 1, 2013Chemotherapy regimens in early breast cancer: major controversies and future outlook
Feb 1, 2013Expert Rev Anticancer Ther 2013; 13:165-78
Jörger Markus, Thürlimann Beat
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
Oakman C, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber R, Piccart-Gebhart M, Viale G, Gutiérrez J, Thürlimann B, Jakesz R, Francis P, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Di Leo A. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. Ann Oncol 2013; 24:1203-11.
Jan 4, 2013Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
Jan 4, 2013Ann Oncol 2013; 24:1203-11
Oakman C, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber R D, Piccart-Gebhart M, Viale G, Gutiérrez J, Thürlimann Beat, Jakesz R, Francis P A, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Di Leo A
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.
Oct 8, 2012Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Oct 8, 2012J Clin Oncol 2012; 30:3967-75
Ewertz Marianne, Goldhirsch Aron, Coates Alan S, Smith Ian E, Láng István, Colleoni Marco, Gelber Richard D, Rabaglio Manuela, Paridaens Robert J, Forbes John F, Bonnefoi Hervé, Thürlimann Beat, Price Karen N, Ejlertsen Bent, Regan Meredith M, Gray Kathryn P, Mouridsen Henning T
Treatment of breast cancer in the elderly: a prospective, population-based Swiss study
Jörger M, Jundt G, Probst-Hensch N, Bordoni A, Konzelmann I, Bouchardy C, Vlastos G, Lütolf U, Rageth C, Frick H, Savidan A, Thürlimann B, Ess S. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2012; 4:39-47.
Aug 24, 2012Treatment of breast cancer in the elderly: a prospective, population-based Swiss study
Aug 24, 2012J Geriatr Oncol 2012; 4:39-47
Jörger Markus, Jundt G, Probst-Hensch N, Bordoni A, Konzelmann I, Bouchardy C, Vlastos G, Lütolf U, Rageth C, Frick H, Savidan A, Thürlimann Beat, Ess S
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Karlsson P, Gruber G, Goldhirsch A, Gelber R, Forbes J, Castiglione-Gertsch M, Crivellari D, Thürlimann B, Kovács A, Collins J, Lindtner J, Price K, Chua B, Cole B, International Breast Cancer Study Group. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012; 23:2852-8.
Jul 9, 2012Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Jul 9, 2012Ann Oncol 2012; 23:2852-8
Karlsson P, Gruber G, Goldhirsch A, Gelber R D, Forbes J F, Castiglione-Gertsch M, Crivellari D, Thürlimann Beat, Kovács A, Collins J P, Lindtner J, Price K N, Chua B H, Cole B F, International Breast Cancer Study Group
Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Huober J, Regan M, Gelber R, Price K, Öhlschlegel C, Viale G, Coates A, Goldhirsch A, Gelber S, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012; 23:2843-51.
Jun 14, 2012Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Jun 14, 2012Ann Oncol 2012; 23:2843-51
Huober Jens, Regan M M, Gelber R D, Price K N, Öhlschlegel Christian, Viale G, Coates A S, Goldhirsch A, Gelber S, Thürlimann Beat
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Phillips K, Aldridge J, International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012; 106:1618-25.
Apr 24, 2012Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Apr 24, 2012Br J Cancer 2012; 106:1618-25
Ribi K, BIG 1-98 Collaborative Group, Bernhard J, Gelber R D, Price K N, Goldhirsch A, Coates A S, Pagani O, Cardoso F, Thürlimann Beat, Harvey V, Thompson A, Phillips K-A, Aldridge J, International Breast Cancer Study Group
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
Jörger M, ess s, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann I, Thürlimann B. A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer. Swiss Med Wkly 2012; 142:w13571.
Apr 11, 2012A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
Apr 11, 2012Swiss Med Wkly 2012; 142:w13571
Jörger Markus, ess silvia, Dehler Silvia, Savidan Anita, Bouchardy Christine, Frick Harald, Konzelmann Isabelle, Thürlimann Beat
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.
Mar 6, 2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Mar 6, 2012J Natl Cancer Inst 2012; 104:441-51
Regan Meredith M, Debled Marc, Maibach Rudolf, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Rae James M, Viale Giuseppe, Neven Patrick, Ditzel Henrik J, Lyng Maria B, Leyland-Jones Brian, Bouzyk Mark, Pagani Olivia, Tang Weining, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Breast International Group (BIG) 1-98 Collaborative Group